Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT?

Samuel T Wilkinson1, Gerard Sanacora1

  • 1Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.

Depression and Anxiety
|April 16, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using connectome-based predictive models to reveal the systems standardized tests and clinical symptoms are reflecting.

Nature communications·2026
Same author

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental & clinical pharmacology·2026
Same author

Lower synaptic density in mood circuitry underlies depression in Parkinson's disease.

Brain communications·2026
Same author

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.

The Journal of clinical psychiatry·2026
Same author

Concurrent SSRI, SNRI, or Other Antidepressant Use Not Associated With Differential Outcomes in Ketamine or Esketamine Treatment.

The Journal of clinical psychiatry·2026
Same author

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

The British journal of psychiatry : the journal of mental science·2026

Ketamine shows promise for rapidly reducing suicidal ideation (SI), but its effects are temporary. More research is needed to confirm its effectiveness and safety for this critical patient group.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Ketamine is recognized for its rapid antidepressant properties.
  • There is significant interest in ketamine for acute suicide risk management.

Purpose of the Study:

  • To review existing evidence on ketamine's effects on suicidal ideation (SI).
  • To assess the preliminary efficacy and limitations of ketamine for treating SI.

Main Methods:

  • Review of open-label and randomized controlled trials (RCTs) examining ketamine's impact on SI.
  • Analysis of study data regarding the speed and duration of ketamine's effects.

Main Results:

  • Ketamine demonstrated a rapid, though transient, reduction in SI across studies.
Keywords:
antidepressantdepressionketaminesuicidal ideationsuicide

Related Experiment Videos

  • Some studies reported mixed results depending on assessment timing and methods.
  • Limitations include small sample sizes, patient exclusion criteria, and potential placebo unblinding.

    • Conclusions:

    • Current evidence for ketamine's efficacy in treating SI is preliminary.
    • Ketamine is a potentially promising option for patients at imminent suicide risk.
    • Further controlled trials are essential to guide clinical recommendations.